What Are Treatment Options for Pediatric Onycomycosis?
Discussion Onycomycosis is a fungal infection of the nails. It has a world-wide prevalence of 0.3% with some geographical variations such as in the U.S. it is 0.44%. It is an uncommon problem especially in children. It is very uncommon in those under 6 years and only very sporadic case reports in those under 2 years. The lower incidence is felt to be due to children’s faster nail growth, smaller surface to infect, reduced exposure to fungi, lower prevalence of tinea pedis and especially less cumulative trauma. Onycomycosis is more common in families (unsure if this is due to genetic factors or family members having m...
Source: PediatricEducation.org - April 8, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Advice on metyrapone supply issue
There is a manufacturing supply issue with metyrapone (not UK-specific) that is likely to last some months. As the UK uses more of this drug than ketoconazole for Cushing’s patients this is clearly a big issue and some patients may need switching to ketoconazole, or to be considered for other treatments. The medical community might be able to influence a reduction in metyrapone use by altering some prescribing practice.  This would ensure more is available for patients who are on longer term treatment or have very severe disease. For patients who are awaiting pituitary surgery in centres that pr...
Source: Society for Endocrinology - February 13, 2019 Category: Endocrinology Source Type: news

Ketoconazole (Nizoral) 2% Shampoo (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 19, 2018 Category: Drugs & Pharmacology Source Type: news

Extina (Ketoconazole Foam, 2%) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 30, 2018 Category: Drugs & Pharmacology Source Type: news

Ketoconazole vs. Selenium Sulfide
Title: Ketoconazole vs. Selenium SulfideCategory: MedicationsCreated: 1/5/2018 12:00:00 AMLast Editorial Review: 1/5/2018 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - January 5, 2018 Category: Dermatology Source Type: news

Xolegel (Ketoconazole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2017 Category: Drugs & Pharmacology Source Type: news

Nizoral Shampoo (Ketoconazole 2%) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 20, 2016 Category: Drugs & Pharmacology Source Type: news

Ketoconazole Cream (Ketoconazole Cream) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2016 Category: Drugs & Pharmacology Source Type: news

Déjà vu: An FDA warning about oral ketoconazole ... again
The Food and Drug Administration issued a health warning on May 16th, 2016, regarding the use of oral ketoconazole for the treatment of skin and nail dermatophyte and candidal infections – wait what? Why is this even an active discussion? Let’s take a step back: In July 2013, the FDA strengthened... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 3, 2016 Category: Dermatology Source Type: news

FDA Drug Safety Communication: FDA warns that prescribing of ketoconazole oral tablets for unapproved uses including skin and nail infections continues; linked to patient death
[05-19-2016] The U.S. Food and Drug Administration (FDA) is warning health care professionals to avoid prescribing the antifungal medicine ketoconazole oral tablets to treat skin and nail fungal infections. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 20, 2016 Category: Drugs & Pharmacology Source Type: news

Oral Ketoconazole Shouldn't Be Given for Skin and Nail Fungal Infections (FREE)
By Kelly Young Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS The oral antifungal ketoconazole (Nizoral) should not be used to treat skin and … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 19, 2016 Category: Primary Care Source Type: news

Death Risk With Off-Label Oral Ketoconazole Use, FDA Warns Death Risk With Off-Label Oral Ketoconazole Use, FDA Warns
Clinicians continue to prescribe ketoconazole tablets for skin and nail fungal infections, even though the FDA withdrew those indications in 2013 in light of the risk for liver damage and death. News Alerts (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 19, 2016 Category: Dermatology Tags: Dermatology News Alert Source Type: news

FDA: No oral ketoconazole for skin, nail fungus
The Food and Drug Administration is warning health care professionals not to prescribe oral ketoconazole for patients with fungal infections of the skin and nails, because of "the risks of... (Source: Pediatric News)
Source: Pediatric News - May 19, 2016 Category: Journals (General) Source Type: news

FDA: No oral ketoconazole for skin, nail fungus
The Food and Drug Administration is warning health care professionals not to prescribe oral ketoconazole for patients with fungal infections of the skin and nails, because of "the risks of serious liver damage, adrenal gland problems, and harmful interactions with other medicines that... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 19, 2016 Category: Dermatology Source Type: news

FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death
[05-19-2016] The U.S. Food and Drug Administration (FDA) is warning health care professionals to avoid prescribing the antifungal medicine ketoconazole oral tablets to treat skin and nail fungal infections. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 19, 2016 Category: Drugs & Pharmacology Source Type: news